Home  >  TopNews
you can get e-magazine links on WhatsApp.Click here
Pioma_Lactic
Clinical Trials + Font Resize -

Parexel India to grow talent pool and clinical expertise

Yash Ved, Mumbai
Thursday, September 23, 2021, 08:00 Hrs  [IST]

Parexel India, which provides the most comprehensive drug development capabilities of any clinical research organization (CRO), stated that it is looking to continue to grow talent pool and clinical expertise that touch upon different areas of clinical conduct ranging from study support to data analytics and patient innovations.

The company stated that collaborating with local universities, it has developed the Parexel India Academy, which is further helping the company to define and influence the educational curriculum to include real-life expectations and expertise that will help build talent for Parexel and the broader clinical and pharma industry.

“Decreasing approval timelines for applications and improved understanding of the subject through the involvement of industry knowledge experts are key drivers for India's clinical trial regulation landscape to evolve and stay poised to pioneer important discoveries post pandemic”, stated Sanjay Vyas, executive VP, India country head & MD, SBU head – clinical trial supplies & logistics, Parexel.

Parexel India operations team currently includes more than 5,100 people deployed in over 18 clinical functions supporting global, local and regional study conduct. These clinical functions include global safety services, pharmacovigilance, global data organization, medical writing, data management, stats programming, and bio-statistics.

The company added that its India operations team also includes finance and HR services that constitute 10 to 15% of total employee strength and combined, India represents 25% of the total global employee population at Parexel.

The company also adopted a more flexible operating model that allows colleagues to work in hybrid and decentralized models, allowing it to attract talent across India to support global company demands.

“At Parexel, we remain steadfast in our patients-first focus to help drive innovations. We continue to look for ways to put patients at the heart of everything we do and to simplify the way we do business to better benefit our patients, sponsors and investigator sites. We are also leveraging and growing our strong therapeutic SME capabilities and expertise around the world. This is possible by further continuing to empower and engage our people in making and influencing patient centric decisions,” stated Vyas.

Parexel has a strong focus in driving and executing diversity, equity & inclusion strategy both internally as an organization and also how we can positively influence diversity in clinical research by ensuring diverse patient populations within our studies.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |